Home › Companies › ATEA PHARMACEUTICALS INC. › 2023-2024

ATEA PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ATEA PHARMACEUTICALS INC.’s Form 8-K, filed June 21, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.

4Ballot items
127Asset managers
688Fund votes
June 21, 2024Meeting date

Results at a glance

Meeting of June 21, 2024: 4 items on ATEA PHARMACEUTICALS INC.’s Form 8-K, filed June 21, 2024: 1 approved · 3 without a stated outcome.

Material dissent

Elect Director: Franklin Berger 51.8% of votes cast Outcome not stated Director under 80%
Elect Director: Jean-Pierre Sommadossi, Ph.D. 69% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ATEA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ATEA PHARMACEUTICALS INC.

These tallies are ATEA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 21, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ATEA PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 21, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Franklin Berger	30,459,345	--	--	28,342,583	15,563,551	51.8%	Not verified	—
Elect Director: Jean-Pierre Sommadossi, Ph.D.	40,751,581	--	--	18,050,347	15,563,551	69%	Not verified	—
2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024	62,300,216	6,472,069	5,593,194	--	0	91%	Not verified	—
3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers	42,900,395	15,499,499	402,034	--	15,563,551	73%	Approved	—

Source: ATEA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 21, 2024 — read the filing on EDGAR.

How asset managers voted at the ATEA PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 127 asset managers that disclosed a ATEA PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Franklin Berger

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

51.8% Majority: yes · of votes cast

FOR 51.8%WITHHELD

FOR: 30,459,345WITHHELD: 28,342,583

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of Class I Directors: Franklin Berger

ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Franklin Berger”): 30,459,345 for, 28,342,583 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 51.8% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 10,499,621 for, 5,729,558 withheld, 64,968 abstained.

FORWITHHOLD

FOR: 10,499,621ABSTAIN: 64,968WITHHOLD: 5,729,558

Largest asset managers voting on “Election of Class I Directors: Franklin Berger” at ATEA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	4,653,782	0	0	For
Fidelity	4,203,719	0	111,837	For
BlackRock	0	0	4,167,442	Withhold
Charles Schwab	614,008	0	0	For
Federated Hermes	549,380	0	0	For
Dimensional	0	0	323,733	Withhold
TIAA	289,493	0	0	For
Equitable	0	0	252,288	Withhold
QUANTITATIVE MASTER SERIES LLC	0	0	146,690	Withhold
American Century	0	0	111,835	Withhold
Nationwide	0	0	109,933	Withhold
Columbia Threadneedle	105,243	0	0	For
Delaware/Macquarie	0	0	70,000	Withhold
Lincoln Financial	0	0	67,325	Withhold
MASTER INVESTMENT PORTFOLIO	0	0	59,077	Withhold
ALPS ETF Trust	0	0	58,907	Withhold
T. Rowe Price	49,020	0	0	For
AIG/SunAmerica	0	0	37,779	Withhold
GuideStone	0	0	36,540	Withhold
Bridge Builder Trust	0	31,709	0	Abstain
Pacific Life	0	0	30,628	Withhold
John Hancock	0	30,359	0	Abstain
Voya	0	0	28,547	Withhold
State Street	0	0	24,839	Withhold
ProShares	0	0	20,795	Withhold

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

2. Elect Director: Jean-Pierre Sommadossi, Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

69% Majority: yes · of votes cast

FOR 69%WITHHELD

FOR: 40,751,581WITHHELD: 18,050,347

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of Class I Directors: Jean-Pierre Sommadossi, Ph.D.

ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jean-Pierre Sommadossi, Ph.D.”): 40,751,581 for, 18,050,347 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 69% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 15,398,044 for, 862,844 withheld, 33,259 abstained.

FOR

FOR: 15,398,044ABSTAIN: 33,259WITHHOLD: 862,844

Largest asset managers voting on “Election of Class I Directors: Jean-Pierre Sommadossi, Ph.D.” at ATEA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	4,653,782	0	0	For
Fidelity	4,314,456	0	1,100	For
BlackRock	4,167,442	0	0	For
Charles Schwab	614,008	0	0	For
Federated Hermes	549,380	0	0	For
Dimensional	0	0	323,733	Withhold
TIAA	289,493	0	0	For
Equitable	252,288	0	0	For
QUANTITATIVE MASTER SERIES LLC	146,690	0	0	For
American Century	0	0	111,835	Withhold
Nationwide	0	0	109,933	Withhold
Columbia Threadneedle	105,243	0	0	For
Delaware/Macquarie	0	0	70,000	Withhold
Lincoln Financial	63,300	0	4,025	Mixed
MASTER INVESTMENT PORTFOLIO	59,077	0	0	For
ALPS ETF Trust	0	0	58,907	Withhold
T. Rowe Price	49,020	0	0	For
AIG/SunAmerica	0	0	37,779	Withhold
GuideStone	0	0	36,540	Withhold
Bridge Builder Trust	31,709	0	0	For
Pacific Life	30,628	0	0	For
John Hancock	0	30,359	0	Abstain
Voya	0	0	28,547	Withhold
State Street	24,839	0	0	For
ProShares	0	0	20,795	Withhold

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

3. 3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 11 wordings of this item as funds reported it.

73% Approved · of votes cast

FOR 73%AGAINST

FOR: 42,900,395AGAINST: 15,499,499

Details: description as filed, official tally, votes by 127 asset managers

Description as filed by funds: Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Company.

ATEA PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 42,900,395 for, 15,499,499 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Item 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.”
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 42 asset managers voting on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Comp” at ATEA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	4,653,782	0	For
Fidelity	4,315,556	0	For
BlackRock	4,167,442	0	For
Charles Schwab	0	614,008	Against
Federated Hermes	549,380	0	For
Dimensional	0	323,733	Against
TIAA	289,493	0	For
Equitable	252,288	0	For
QUANTITATIVE MASTER SERIES LLC	146,690	0	For
American Century	0	111,835	Against
Nationwide	109,933	0	For
Columbia Threadneedle	105,243	0	For
Delaware/Macquarie	70,000	0	For
Lincoln Financial	63,300	4,025	Mixed
MASTER INVESTMENT PORTFOLIO	59,077	0	For
ALPS ETF Trust	58,907	0	For
T. Rowe Price	49,020	0	For
AIG/SunAmerica	37,779	0	For
GuideStone	36,540	0	For
Bridge Builder Trust	31,709	0	For
Pacific Life	30,628	0	For
John Hancock	30,359	0	For
Voya	28,547	0	For
State Street	24,839	0	For
ProShares	20,795	0	For

Fund voting reports, all 42 managers: 15,213,441 for, 1,080,706 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 97 asset managers voting on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Comp” at ATEA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
EcoR1 Capital, LLC	0	6,145,861	Against
Fidelity	5,871,848	0	For
BlackRock	3,220,008	25,994	For
Bain Capital Life Sciences Investors, LLC	2,485,638	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,906,463	0	For
State Street	1,580,404	1,925	For
Renaissance	1,006,262	0	For
Northern Trust	620,877	103	For
Charles Schwab	0	614,008	Against
Federated Hermes	553,421	0	For
Two Sigma	462,586	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	457,854	0	For
Newtyn Management, LLC	400,000	0	For
ACADIAN ASSET MANAGEMENT LLC	370,937	0	For
Wellington	0	313,700	Against
Nuveen	291,091	0	For
MELLON INVESTMENTS Corp	268,328	0	For
Citadel	245,662	0	For
Allianz	0	226,574	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	200,628	0	For
DE Shaw	194,093	0	For
STATE OF WISCONSIN INVESTMENT BOARD	119,400	0	For
AllianceBernstein	116,420	0	For
American Century	0	111,835	Against
MARSHALL WACE, LLP	0	109,509	Against

Institutional-manager reports, all 97 managers: 21,083,273 for, 8,071,773 against. Showing the 25 largest; see all in the interactive database.

4. 2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%

FOR: 62,300,216AGAINST: 6,472,069

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

ATEA PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024”): 62,300,216 for, 6,472,069 against, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 16,294,147 for.

FOR

FOR: 16,294,147

Largest asset managers voting on “Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fisca” at ATEA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
Vanguard	4,653,782	For
Fidelity	4,315,556	For
BlackRock	4,167,442	For
Charles Schwab	614,008	For
Federated Hermes	549,380	For
Dimensional	323,733	For
TIAA	289,493	For
Equitable	252,288	For
QUANTITATIVE MASTER SERIES LLC	146,690	For
American Century	111,835	For
Nationwide	109,933	For
Columbia Threadneedle	105,243	For
Delaware/Macquarie	70,000	For
Lincoln Financial	67,325	For
MASTER INVESTMENT PORTFOLIO	59,077	For
ALPS ETF Trust	58,907	For
T. Rowe Price	49,020	For
AIG/SunAmerica	37,779	For
GuideStone	36,540	For
Bridge Builder Trust	31,709	For
Pacific Life	30,628	For
John Hancock	30,359	For
Voya	28,547	For
State Street	24,839	For
ProShares	20,795	For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

Largest ATEA PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 84,223,100 shares outstanding at the time of that meeting.

Fund voting reports: top ATEA PHARMACEUTICALS INC. shareholders by shares voted on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	5.53%
2	Fidelity	5.12%
3	BlackRock	4.95%
4	Charles Schwab	0.73%
5	Federated Hermes	0.65%
6	Dimensional	0.38%
7	TIAA	0.34%
8	Equitable	0.30%
9	QUANTITATIVE MASTER SERIES LLC	0.17%
10	American Century	0.13%

Institutional-manager reports: top ATEA PHARMACEUTICALS INC. shareholders by shares voted on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive…”, 2023-2024
#	Asset manager	% of shares outstanding
1	EcoR1 Capital, LLC	7.30%
2	Fidelity	6.97%
3	BlackRock	3.85%
4	Bain Capital Life Sciences Investors, LLC	2.95%
5	GEODE CAPITAL MANAGEMENT, LLC	2.26%
6	State Street	1.88%
7	Renaissance	1.19%
8	Northern Trust	0.74%
9	Charles Schwab	0.73%
10	Federated Hermes	0.66%

Reported ATEA PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ATEA PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
BlackRock	10.04%	13F
FMR (Fidelity)	6.91%	13F
Vanguard Group	5.59%	13F
Geode Capital	2.24%	13F
State Street	1.99%	13F
Renaissance Technologies	1.33%	13F
Northern Trust	0.82%	13F
JPMorgan Chase	0.73%	13F
Charles Schwab	0.73%	13F
Morgan Stanley	0.53%	13F

Percentages above are of 84,223,100 shares outstanding, as reported by ATEA PHARMACEUTICALS INC. on its Form 10-Q dated May 13, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ATEA PHARMACEUTICALS INC.’s 10-Q dated May 13, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At ATEA PHARMACEUTICALS INC.'s shareholder meeting held June 21, 2024, in the 2023-2024 proxy season, 127 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 688 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory (non- binding) basis, of the compensation of the named executive… — ATEA PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 73% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ATEA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 21, 2024.

ATEA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.